Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2024

Open Access 01-12-2024 | Enoxaparin | Research

Prophylaxis with enoxaparin and antithrombin III in drug-induced coagulation alterations in childhood leukemia: a retrospective experience of 20 years

Authors: Christina Salvador, Robert Salvador, Gabriele Kropshofer, Bernhard Meister, Marie Rock, Petra Obexer, Benjamin Hetzer, Evelyn Rabensteiner, Roman Crazzolara

Published in: Thrombosis Journal | Issue 1/2024

Login to get access

Abstract

Background

Thromboembolic complications are well known in the treatment of childhood acute lymphoblastic leukemia. Over the years it has not been possible to reach a consensus on a possible prophylaxis of thromboembolic events during intensive therapy. Only the administration of enoxaparin was able to achieve evidence in the literature to date.

Methods

In this retrospective study, 173 childhood leukemia patients were treated over 20 years with a thromboembolic prophylaxis including enoxaparin and AT III during induction therapy with L-asparaginase and cortisone.

Results

We here report the effectiveness of administration of enoxaparin and AT III in childhood leukemia, showing a strikingly low prevalence of deep vein thrombosis (2.9%). Especially in adolescent patients, a particularly great need for AT III was demonstrated.

Conclusions

We recommend thromboembolic prophylaxis with enoxaparin and AT III substitution during induction/reinduction therapy with L-asparaginase and glucocorticosteroids, especially from adolescence onwards.
Literature
1.
Nowak-Göttl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol. 2009;22(1):103–14.CrossRefPubMed
2.
Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L’Asparaginase-induced antithrombin III deficiency. Blood. 1994;83(2):386–91.CrossRefPubMed
3.
Mitchell LG, Halton JM, Vegh PA, Barr RD, Venneri T, Pai KM, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol. 1994;16(2):120–6.PubMed
4.
Ismail MM, Hamed GM. Activity levels of natural anticoagulant proteins in childhood acute lymphoblastic leukemia: relation to thromboembolic complications and treatment. Blood Coagul Fibrinolysis. 2017;28(1):1–7.CrossRefPubMed
5.
Biss TT, Payne JH, Hough RE, Grainger JD, Macartney C, Sibson KR, et al. Strategies to prevent and manage thrombotic complications of acute lymphoblastic leukemia in children and young people vary between centers in the United Kingdom. J Pediatr Hematol Oncol. 2016;38(3):221–6.CrossRefPubMed
6.
Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50(2):298–303.CrossRefPubMed
7.
Pelland-Marcotte MC, Tole S, Pechlivanoglou P, Brandão LR. Effectiveness and safety of primary thromboprophylaxis in children with cancer: a systematic review of the literature and network meta-analysis. Thromb Haemost. 2019;119(12):2034–42.CrossRefPubMed
8.
Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R, et al. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019;104(4):756–65.CrossRefPubMedPubMedCentral
9.
Klaassen ILM, Lauw MN, van de Wetering MD, Biemond BJ, Middeldorp S, Abbink FCH, et al. TropicALL study: thromboprophylaxis in children treated for acute lymphoblastic leukemia with low-molecular-weight heparin: a multicenter randomized controlled trial. BMC Pediatr. 2017;17(1):122.CrossRefPubMedPubMedCentral
10.
O’Brien SH, Li D, Mitchell LG, Hess T, Zee P, Yee DL, et al. PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric Acute Lymphoblastic Leukaemia (ALL)-rationale and design. Thromb Haemost. 2019;119(5):844–53.CrossRefPubMed
11.
Mall V, Thomas KB, Sauter S, Niemeyer CM, Sutor AH. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr. 1999;211(4):205–10.CrossRefPubMed
12.
Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost. 1995;21(4):390–401.CrossRefPubMed
13.
Ishihara T, Nogami K, Ochi S, Ishida T, Kosaka Y, Sawada A, et al. Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(1): e28016.CrossRefPubMed
14.
Risseeuw-Appel IM, Dekker I, Hop WC, Hählen K. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study. Med Pediatr Oncol. 1994;23(4):335–43.CrossRefPubMed
15.
Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) study. Cancer. 2003;97(2):508–16.CrossRefPubMed
16.
Ghanem KM, Dhayni RM, Al-Aridi C, Tarek N, Tamim H, Chan AKC, Saab R, Abboud MR, El-Solh H, Muwakkit SA. Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management. Pediatr Blood Cancer. 2017;64(12). https://​doi.​org/​10.​1002/​pbc.​26694. Epub 2017 Jun 29.
17.
Gidl A, Füreder A, Benesch M, Dworzak M, Engstler G, Jones N, et al. Incidence and risk factors of venous thromboembolism in childhood acute lymphoblastic leukaemia - a population-based analysis of the Austrian Berlin-Frankfurt-Münster (BFM) study group. Pediatr Hematol Oncol. 2023;40(2):181–91.CrossRefPubMed
18.
Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost. 2008;100(2):330–7.PubMed
19.
Prasca S, Carmona R, Ji L, Ko RH, Bhojwani D, Rawlins YA, et al. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thromb Res. 2018;165:44–50.CrossRefPubMedPubMedCentral
20.
Rank CU, Lynggaard LS, Als-Nielsen B, Stock W, Toft N, Nielsen OJ, et al. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020;10(10):Cd013399.PubMed
21.
Halton JM, Mitchell LG, Vegh P, Eves M, Andrew ME. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am J Hematol. 1994;47(3):157–61.CrossRefPubMed
22.
Klaassen ILM, Zuurbier CCM, Hutten BA, van den Bos C, Schouten AYN, Stokhuijzen E, et al. Venous thrombosis in children with acute lymphoblastic leukemia treated on DCOG ALL-9 and ALL-10 protocols: the effect of fresh frozen plasma. TH Open. 2019;3(2):e109–16.CrossRefPubMedPubMedCentral
23.
Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2001;12(5):367–70.CrossRefPubMed
24.
Nowak-Göttl U, Kuhn N, Wolff JE, Boos J, Kehrel B, Rath B, et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol. 1996;56(1–2):35–8.CrossRefPubMed
25.
Pelland-Marcotte MC, Amiri N, Avila ML, Brandão LR. Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children. Cochrane Database Syst Rev. 2020;6(6):Cd005982.PubMed
26.
Czogała M, Balwierz W, Sztefko K, Rogatko I. Antithrombin III as the indicator of L-asparaginase activity in children treated for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2017;39(2):114–20.CrossRefPubMed
Metadata
Title
Prophylaxis with enoxaparin and antithrombin III in drug-induced coagulation alterations in childhood leukemia: a retrospective experience of 20 years
Authors
Christina Salvador
Robert Salvador
Gabriele Kropshofer
Bernhard Meister
Marie Rock
Petra Obexer
Benjamin Hetzer
Evelyn Rabensteiner
Roman Crazzolara
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2024
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-024-00602-x

Other articles of this Issue 1/2024

Thrombosis Journal 1/2024 Go to the issue

Research

Exercise transiently increases the density of incipient blood clots in antiplatelet-treated lacunar stroke patients

Review

Managing the VTE risk in patients with CTD-ILD

Research

Nomogram for hospital-acquired venous thromboembolism among patients with cardiovascular diseases

Research

Detecting prokaryote-specific gene and other bacterial signatures in thrombi from patients with acute ischemic stroke

Research

Factors influencing DVT formation in sepsis

Research

SERPINC1 c.1247dupC: a novel SERPINC1 gene mutation associated with familial thrombosis results in a secretion defect and quantitative antithrombin deficiency
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits